The automated and closed cell therapy processing system market is expected to expand at a 22.8% CAGR from 2023 to 2033. This market is estimated to value from USD 1,199.14 million in 2023 to USD 9,350.92 million in 2033.Increasing Integration of Software Technologies and Sophisticated Therapy Development Procedures is also Expected to Drive Market Growth.
For controlling and sustaining the cell therapy process, automated and closed cell therapy processing systems are used. The system includes manufacturing software and hardware, which aids in the entire research and development process. The technology is a gift to researchers because it assists them in clinical studies through commercial approval. This can aid in the development and avoidance of manual manufacturing delays. Several scale levels of standardisation can be accomplished for diverse production processes.
Researchers believe automated and closed cell therapy processing systems to be simple to use and dependable, as they aid in converting cell therapy from discovery to commercialization.
The increasing number of investments in the market for automated and closed cell therapy processing systems is the key driver of market expansion in the next years. Furthermore, the growing number of cell therapies provides the market with profitable potential. Cell treatment processing is a critical activity that necessitates extreme precision while treating the cells.
The usage of physical labor has been determined to be inefficient because it increases the risk of the process. Also, manual processing increases the possibility of contamination. As a result, the combination of advanced medicines and automated systems is quickly rising.
The adoption of automated systems has aided in the centralization of cell therapy processes, which has benefited manufacturers in a variety of ways.
| Report Attribute | Details |
|---|---|
| Automated and Closed Cell Therapy Processing System Market Value (2023) | USD 1199.14 million |
| Automated and Closed Cell Therapy Processing System Market Anticipated Value (2033) | USD 9350.92 million |
| Automated and Closed Cell Therapy Processing System Market Growth Rate (2023 to 2033) | 22.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The automated and closed cell therapy processing system market accounted for USD 976.50 million in 2022, expanding at a 22.4% CAGR from 2018 to 2022.
Cell therapy technologies are critical in medicine and the cell therapy sector, which has arisen as a crucial factor in medical practice. Furthermore, various cell treatment approaches share functions such as medication delivery, gene therapy, cancer vaccinations, tissue engineering, and regenerative medicine. The distribution of cell therapy products can range from injections to surgical implantation using specialized equipment.
The increasing popularity of regenerative medicines and cell therapies is one of the important factors driving the market growth. The multiple advantages afforded by automation technologies for the development of these therapies are further driving market expansion. Furthermore, the increasing mix of software technologies and complex therapy development techniques is bolstering the market growth.
| Historical CAGR (2018 to 2022) | 22.4% |
|---|---|
| Forecast CAGR (2023 to 2033) | 22.8% |
As per the FMI analysts, a valuation of USD 9350.92 million by 2033 end is estimated for the market.
| Year | Market Valuation |
|---|---|
| 2016 | USD 284.76 million |
| 2021 | USD 795.20 million |
| 2022 | USD 976.50 million |
| 2023 | USD 1199.14 million |
| 2033 | USD 9350.92 million |
Regenerative medicine is a branch of medicine that involves the replacement of damaged tissues or organs. Regenerative medicine is concerned with replacing and rebuilding tissue or organ damage caused by a specific disease or event.
The growing importance of stem cells in regenerative medicine results in increasing demand for regenerative medicine from the healthcare industry. This factor remains a significant factor driving the creation of automated and closed-cell therapy processing systems.
Cancer and other chronic diseases that require long-term therapy have increased the popularity of regenerative medicine. Stem cell uses are part of regenerative medicine. Stem cells can be divided indefinitely and are employed as a first-line source for regenerative therapy.
Regenerative medicine is a branch of medicine that uses various methods to repair, regrow, or replace diseased or damaged cells, organs, or tissues. Furthermore, regenerative medicine encompasses the synthesis and application of therapeutic stem cells, tissue development, and the creation of artificial organs. Due to their high accuracy and effectiveness, regenerative medicines and cell therapies are expected to see a surge in demand, driving the market growth.
Principal Consultant
Chronic disease refers to a category of diseases that include cardiovascular disease, cancer, and diabetes, among others. The global population is experiencing an increase in the prevalence of chronic diseases. It is primarily linked to sedentary behavior, an unhealthy diet, and cigarette use.
Chronic disease, according to the USA Centers for Disease Control and Prevention (CDC), is a condition that lasts longer than a year. This disease requires prompt medical attention. It limits everyday activities also.
As cell therapies become popular, the market for automated processing systems needs experienced personnel to perform these therapies and operate automated systems. The shortage of skilled specialists, on the other hand, is expected to stymie the expansion of the automated and closed cell therapy processing system market over the forecast period.
The use of technologically advanced and extremely intricate flow cytometers and spectrophotometers to generate a large number of data outputs that require knowledge to comprehend and assess might impede the market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The complete cell therapy manufacturing process is made up of several phases, each of which requires a starting material. The global need for automated and closed-cell therapy processing systems has resulted in a scarcity of raw materials required for good medical practice (GMP).
The market is experiencing a bottleneck in the supply of plasmids and viral vectors, which are proven GMP-based raw materials necessary in the cell therapy process.
The difficulties in procuring starting materials such as bone marrow, blood, and apheresis provide a hindrance to the market's expansion. As a result, the global automated and closed-cell therapy processing system market is constrained by a scarcity of raw materials.
Governments and big pharmaceutical corporations are investing in research and development to accelerate the discovery of new therapies for a variety of health ailments. Increasing research and development investment in cell therapy research might promote market expansion by facilitating the discovery of novel automated and closed-cell therapies.
Increased research and development efforts in the pharmaceutical sector are expected to provide significant income for the market.
The United States of America with a CAGR of 20.7% from 2015 to 2021 is the prominent market for automated and closed cell therapy. The market for automated and closed cell therapy processing systems in the United States of America is expected to cross USD 2.2 million by the end of 2032 with an absolute dollar opportunity of USD 1.9 Million.
The market in the United Kingdom is expected to reach a valuation of USD 312 million by 2032. Growing at a CAGR of 21.2%, the market in the country is projected to cross an absolute dollar opportunity of USD 155.3 million from 2022 to 2032.
In Japan, the market is projected to register a CAGR of 24.1% during the forecast period. With an absolute dollar opportunity of USD 262 million from 2022 to 2032, the market in the country is expected to reach USD 296 million by 2032.
The market in South Korea is expected to reach USD 193 million by 2032. With a CAGR of 26.1% during the forecast period, the market is expected to register an absolute dollar opportunity of USD 173 Million.
The separation workflow category is predicted to expand significantly in the automated and closed-cell therapy processing system market. Separation is an important component of the closed-cell therapy processing system.
Separation of cell components is required for doing the research in a timely manner. The cell separation revealed minute data about genetic modification, molecular analysis, hybridoma creation, and so on. As a result, cell separation is critical for future research and development in research and academic contexts.
The market for the Non-Stem Cell Therapy type expanded at a CAGR of 17.2% from 2015 to 2021. The success of CAR-T therapies has shifted investment to non-stem cell therapy development, resulting in increased revenue for the industry.
Companies in the market are hugely collaborating and forming partnerships in order to create new regenerative therapies for the treatment of chronic diseases. Such research efforts are primarily focused on non-stem cell uses, which is fueling the non-stem cell treatment segment's expansion.
The enormous therapeutic potential of cell and tissue-based engineering is predicted to allow the segment to increase at a notable rate during the forecast period.
Some of the recent developments of automated and closed cell therapy processing System Market providers are as follows:
| Attribute | Details |
|---|---|
| Market Size Value In 2023 | USD 1199.14 million |
| Market Size Value in End of Forecast (2033) | USD 9350.92 million |
| Market Analysis | USD million for Value |
| Key Region Covered | North America; Europe; Asia Pacific; Latin America; The Middle East & Africa |
| Key Segments | By Type, By Workflow, By Scale, By Region |
| Key Companies Profiled | Miltenyi Bio tec; Lonza; Fresenius Kabi; Cytiva; Bio Spherix; Terumo; Cellares; Sartorius |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The automated and closed cell therapy processing systems market size will reach USD 1199.14 million in 2023.
The automated and closed cell therapy processing systems market is set to surge at a robust 22.8% CAGR, reaching a noteworthy valuation of USD 9350.92 million by 2033.
The automated and closed cell therapy processing systems market demonstrated a 22.4% CAGR from 2018 to 2022, recording a valuation of USD 976.50 million in 2022
The automated and closed cell therapy processing systems market beckons stakeholders with opportunities in innovative medical technologies.
The non-stem cell therapy type demonstrated significant expansion, registering a robust CAGR of 17.2% between 2015 and 2021.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow 5.1. Cryopreservation 5.2. Fill-finish 5.3. Separation 5.4. Expansion 5.5. Apheresis 5.6. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Stem Cell Therapy 6.2. Non-stem Cell Therapy 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale 7.1. Commercial Scale 7.2. R&D Scale 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Lonza 18.2. BioSpherix 18.3. Cellares 18.4. Sortorius 18.5. Cytiva 18.6. ThermoGenesis Holdings Inc. 18.7. Thermo Fisher Scientific Inc. 18.8. MiltenyiBiotec 18.9. Fresenius Kabi 18.10. Pfizer 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Automated and Closed Cell Therapy Processing Systems Market
